FACT SHEET

IPO : Sudeep Pharma Limited Nov 2025

Snapshot

Sudeep Pharma Limited, based in Vadodara, is a leading Indian manufacturer specializing in specialty mineral phosphates and pharmaceutical excipients for the pharmaceutical, nutraceutical, food, and battery industries. The company is recognized as a pioneering battery-grade iron phosphate supplier outside China and is establishing Asia's largest mineral phosphate facility, positioning India as a key regional player in EV battery supply chains. Sudeep Pharma addresses growing global demand for safer, sustainable materials critical for electric vehicles and energy storage.

Opening Date	21-Nov-25
Closing Date	25-Nov-25
Price Band	₹563 to ₹593 per share
Bid Lot	25 Shares
Face Value	₹1 per share
No. of Share	1,50,92,750 shares
Issue Size	(aggregating up to ₹895.00 Cr)
Fresh Issue	(aggregating up to ₹95.00 Cr)
Offer for Sale	(aggregating up to ₹800.00 Cr)

Company Vision

Sudeep Pharma Limited is to emerge as a global leader in specialty mineral phosphates and pharmaceutical excipients by leveraging innovation, quality, and sustainable practices. The company aims to expand its footprint in critical industries like pharmaceuticals, nutraceuticals, food, and battery materials while fostering technological advancement and environmental stewardship. Sudeep Pharma aspires to power the future of healthcare and clean energy through trusted, safe, and high-performance products, driving value for stakeholders and contributing to a healthier planet.

Key Financial

Amount in cr.	Q1 FY2026	FY2025	FY2024	FY2023
Assets	922.3	717.2	513.9	420.1
Total Income	130.1	511.3	465.4	438.3
Profit After Tax	31.3	138.7	133.2	62.3
EBITDA	48.6	199.3	187.8	98.6
NET Worth	688.3	497.5	359.1	226.3
Reserves and Surplus	668.5	481.1	354.6	221.9
Total Borrowing	136.0	135.3	75.0	82.3

Growth Prospects

Sudeep Pharma Limited's growth prospects are anchored in expanding its leadership in specialty mineral phosphates and pharmaceutical excipients amid growing global demand. The company is strategically positioned to capitalize on rising needs in pharmaceuticals, nutraceuticals, food, and electric vehicle battery materials, especially with Asia's largest mineral phosphate facility underway. Strong export presence in key markets, ongoing product innovation, acquisition of Nutrition Supplies and Services Ireland Limited, and favorable government incentives contribute to robust expansion potential.

Risk

Sudeep Pharma Limited faces several risks including customer concentration, regulatory compliance, and operational disruptions. Dependence on a limited number of customers and significant revenue from pharmaceuticals and nutrition segments expose the company to demand fluctuations. Manufacturing facility audits, quality control issues, and regulatory inspections can impact operations and reputation. Export sales are vulnerable to geopolitical risks, tariffs, and trade restrictions.